Literature DB >> 15264431

Gene expression profiling of anticancer immune responses.

Ena Wang1, Monica C Panelli, Vladia Monsurró, Francesco M Marincola.   

Abstract

Anticancer immune responses can be enhanced by immune manipulation, however, the biological mechanism responsible for these immune responses remains largely unexplained. Conventional immunology researchers have extensively studied specific interactions between immune and cancer cells, and additional investigations have identified co-factors that may enhance the effectiveness of such interactions. As the molecular understanding of individual interactions increases, it is becoming apparent that no single mechanism can explain the phenomenon of tumor rejection. The contribution of several components of the innate and adaptive immune response is likely to be required for successful tumor rejection. These components may be variably recruited and activated by molecules with immune modulatory properties being produced by tumor and bystander cells within the tumor micro-environment. Such complexity can only be appreciated and solved by high-throughput tools capable of providing a global view of biological processes as they occur. This review will present selected examples of how high-throughput gene expression profiling may contribute to the understanding of anticancer immune responses. As reviews on technological aspects of the genomic analysis of cancer are already available, this review will provide a speculative discussion about their potential usefulness.

Entities:  

Mesh:

Year:  2004        PMID: 15264431

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN: 1464-8431


  6 in total

Review 1.  Understanding the response to immunotherapy in humans.

Authors:  Ena Wang; Monica C Panelli; Francesco M Marincola
Journal:  Springer Semin Immunopathol       Date:  2005-01-22

Review 2.  Gene-expression profiling in vaccine therapy and immunotherapy for cancer.

Authors:  Davide Bedognetti; Ena Wang; Mario Roberto Sertoli; Francesco M Marincola
Journal:  Expert Rev Vaccines       Date:  2010-06       Impact factor: 5.217

3.  A balanced review of the status T cell-based therapy against cancer.

Authors:  Francesco M Marincola
Journal:  J Transl Med       Date:  2005-04-14       Impact factor: 5.531

4.  Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.

Authors:  Hideaki Tahara; Marimo Sato; Magdalena Thurin; Ena Wang; Lisa H Butterfield; Mary L Disis; Bernard A Fox; Peter P Lee; Samir N Khleif; Jon M Wigginton; Stefan Ambs; Yasunori Akutsu; Damien Chaussabel; Yuichiro Doki; Oleg Eremin; Wolf Hervé Fridman; Yoshihiko Hirohashi; Kohzoh Imai; James Jacobson; Masahisa Jinushi; Akira Kanamoto; Mohammed Kashani-Sabet; Kazunori Kato; Yutaka Kawakami; John M Kirkwood; Thomas O Kleen; Paul V Lehmann; Lance Liotta; Michael T Lotze; Michele Maio; Anatoli Malyguine; Giuseppe Masucci; Hisahiro Matsubara; Shawmarie Mayrand-Chung; Kiminori Nakamura; Hiroyoshi Nishikawa; A Karolina Palucka; Emanuel F Petricoin; Zoltan Pos; Antoni Ribas; Licia Rivoltini; Noriyuki Sato; Hiroshi Shiku; Craig L Slingluff; Howard Streicher; David F Stroncek; Hiroya Takeuchi; Minoru Toyota; Hisashi Wada; Xifeng Wu; Julia Wulfkuhle; Tomonori Yaguchi; Benjamin Zeskind; Yingdong Zhao; Mai-Britt Zocca; Francesco M Marincola
Journal:  J Transl Med       Date:  2009-06-17       Impact factor: 5.531

Review 5.  Reflections upon human cancer immune responsiveness to T cell-based therapy.

Authors:  Ena Wang; Sara Tomei; Francesco M Marincola
Journal:  Cancer Immunol Immunother       Date:  2012-05-11       Impact factor: 6.968

6.  The use of microarray technologies in clinical oncology.

Authors:  L Gabriele; F Moretti; M A Pierotti; F M Marincola; R Foà; F M Belardelli
Journal:  J Transl Med       Date:  2006-02-07       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.